Literature DB >> 3277661

Mucosal involvement in bullous and cicatricial pemphigoid. A clinical and immunopathological study.

V A Venning1, P A Frith, A J Bron, P R Millard, F Wojnarowska.   

Abstract

Thirty-six patients with bullous pemphigoid (BP) and 15 with cicatricial pemphigoid (CP) were studied for evidence of mucosal involvement both clinically and by direct immunofluorescence. Twenty-one patients with BP and all those with CP had lesions of the mucous membranes. Eighteen patients with BP and 14 patients with CP had involvement of the oral mucosa. Lesions of the eyes, nose, pharynx, vulva and urethra also occurred in both groups. The lesions tended to be more widespread in CP patients. Twenty-one patients with BP and 14 with CP were examined by an ophthalmologist. Fine scarring of the tarsal conjunctiva was found in both groups, but also in elderly controls. However, symblepharon occurred in one patient with BP as well as in three patients with CP, but was not seen in a group of 20 controls. Direct immunofluorescence (IF) studies showed linear deposition of IgG or C3 or both in the basement membrane zone of the skin, oral mucosa and conjunctival mucosa in both groups. The frequency of positive immunofluorescence was higher in the conjunctiva than in the lip mucosa or skin in both BP and CP patients. The significance of these findings and the relationship between BP and CP is discussed.

Entities:  

Mesh:

Year:  1988        PMID: 3277661     DOI: 10.1111/j.1365-2133.1988.tb01744.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  9 in total

Review 1.  Autoimmune bullous diseases: ocular manifestations and management.

Authors:  Caroline Laforest; Shyamala C Huilgol; Robert Casson; Dinesh Selva; Igal Leibovitch
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  The 2016 Bowman Lecture Conjunctival curses: scarring conjunctivitis 30 years on.

Authors:  J K Dart
Journal:  Eye (Lond)       Date:  2017-01-20       Impact factor: 3.775

3.  External ocular findings in lupus erythematosus: a clinical and immunopathological study.

Authors:  P Frith; S M Burge; P R Millard; F Wojnarowska
Journal:  Br J Ophthalmol       Date:  1990-03       Impact factor: 4.638

Review 4.  Autoimmune bullous dermatoses in the elderly: diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Autoimmune bullous dermatoses in the elderly: an update on pathophysiology, diagnosis and management.

Authors:  Diya F Mutasim
Journal:  Drugs Aging       Date:  2010-01-01       Impact factor: 3.923

Review 6.  A review of scoring systems for ocular involvement in chronic cutaneous bullous diseases.

Authors:  Brendon W H Lee; Jeremy C K Tan; Melissa Radjenovic; Minas T Coroneo; Dedee F Murrell
Journal:  Orphanet J Rare Dis       Date:  2018-05-22       Impact factor: 4.123

7.  A case series of ocular involvement in bullous pemphigoid: clinical features, management, and outcomes.

Authors:  Anahita Kate; Swapna Shanbhag; Pragnya Rao Donthineni; Sayan Basu
Journal:  F1000Res       Date:  2021-11-25

8.  Juvenile and adult vulvar pemphigoid, an under recognized entity: Case series of fourteen patients.

Authors:  Hanan Rashid; J Marja Oldhoff; Martha Esajas; Gilles F H Diercks; Hendri H Pas; Maria C Bolling; Barbara Horváth
Journal:  JAAD Case Rep       Date:  2021-05-24

9.  European guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part I.

Authors:  H Rashid; A Lamberts; L Borradori; S Alberti-Violetti; R J Barry; M Caproni; B Carey; M Carrozzo; F Caux; G Cianchini; A Corrà; G F H Diercks; F G Dikkers; G Di Zenzo; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; A V Marzano; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; C Prost; S Rauz; B D van Rhijn; M Roth; E Schmidt; J Setterfield; G Zambruno; D Zillikens; B Horváth
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-10       Impact factor: 6.166

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.